Review queue
Why the First Trial Designed to Treat Aging Itself Has Waited Years for a Funder
This page is educational and is not medical advice. It is not advice to start, stop, or change any medication.
The TAME trial (Targeting Aging with Metformin) is a planned study that asks whether one low cost, decades old diabetes pill can delay several diseases of old age at once. The science question is open, but the reason the trial has waited so long is mostly economic. Metformin is off patent and costs very little per dose, so no company can recover the cost of a large trial, and regulators have no approved use called aging for anyone to sell into.[1][2] The scarce input is a funder willing to pay for knowledge that, once produced, belongs to everyone. Solving that problem is a step from scarcity toward abundance: a pill that already exists in huge supply would become tested knowledge that any health system on Earth could use, and the same template could open the door to better drugs that target aging itself.
What the trial is meant to test
The trial was designed by gerontologists brought together with support from a National Institute on Aging grant, and it received planning funding from the American Federation for Aging Research (AFAR), a nonprofit.[3] In a 2016 paper in Cell Metabolism, the lead designers explained why metformin was chosen. It has more than 60 years of use, a strong safety record, and earlier trials and observational studies linking it to lower rates of several age related diseases.[3]
The plan is to enroll 3,000 people aged 65 to 79 at about 14 centers in the United States and follow them for six years, with half taking metformin and half taking a placebo.[3][1][4] The authors stated the purpose plainly: TAME is meant to create a model for testing drugs that delay aging, so that later and better drugs have a path to follow.[3]
The 2015 FDA meeting and the composite endpoint
The Food and Drug Administration (FDA) approves drugs for specific diseases, and it does not treat aging as one.[4] In June 2015, Nature reported that researchers were asking regulators to consider aging a treatable condition.[5] In a 2024 NPR report, one of the scientists involved recalled that a group of researchers went to the FDA that year to ask for a metformin trial aimed at delaying a variety of diseases, and that the agency was receptive.[1]
The design that came out of this work avoids asking the FDA to accept aging as a disease. Instead of measuring aging directly, TAME measures the time until a person develops any one of a cluster of conditions: cardiovascular events, cancer, dementia, or death.[3] If one pill delays the whole cluster, that is evidence it acts on something those diseases share, which is the biology of aging. A 2025 Science|Business report described the FDA's willingness to allow a trial built around protection against any of several age related diseases, rather than a single disease, as a significant step.[6] Related questions about how regulators label and code aging are covered on Classifying aging as a treatable condition and Why WHO dropped old age as a diagnosis.
Why the money never arrived
NPR reported in 2024 that the trial was estimated to cost between 45 and 70 million dollars, and that the National Institutes of Health had set aside about 5 million dollars, which was not enough.[1] The trial's lead fundraiser told NPR that the main obstacle was that metformin is a generic drug, so no pharmaceutical company stood to make money from it, and that the effort had turned to philanthropists and foundations.[1]
In a 2025 Science|Business interview, the same researcher said a billionaire had first been set to fund the trial and then lost his money. A private foundation later agreed to fund only a third of the trial, leaving the team to seek the other two thirds, at an estimated 8 million dollars a year for four to five years. He warned that without more money the trial might have to enroll fewer people.[6]
A September 2026 review of the trial's history reported that, as of mid 2026, TAME was still awaiting funding and had not enrolled a single participant.[2] In an August 2025 interview, the lead researcher said the trial was "now being handled within ARPA-H," the federal Advanced Research Projects Agency for Health, and that he could not give a full update.[7] In March 2026, ARPA-H did fund a different aging trial: up to 38 million dollars for VITAL-H, which will test rapamycin, dapagliflozin, and semaglutide against placebo in 726 adults in their 60s.[8] Metformin is not one of its arms.
An orphan problem, not a metformin problem
TAME is one case of a wider pattern. A 2021 study in the journal Trials found that drug companies are rarely willing to invest in new uses of approved medicines once patent or regulatory protection has ended, which makes these medicines "financial orphans."[9] As a result, new uses for old drugs are mostly studied in independent trials run by universities and research groups, and those groups often cannot pay for the large late stage trials needed to confirm early results.[9]
The irony is that the features that make metformin a good public health candidate are the same features that make it a poor commercial one. If the trial succeeded, its lead fundraiser said, many people could use the drug at once, and it would be something everybody could afford.[1] Low price is a benefit to patients and a barrier to sponsors. Questions about who carries the costs and gains of longer lives are explored further on Who pays for a longer life.
Ways to fund public good trials
The Trials study reviewed several ways to fund research on off patent drugs.[9]
- Government and philanthropic grants are the familiar route and are widely used, but they have so far fallen short for TAME.[9][1]
- Crowdfunding can support small early projects, but the stakeholders interviewed agreed that large clinical trials are too expensive to fund this way.[9]
- Public private partnerships join public bodies and companies around a shared goal, such as access to medicines.[9]
- Social impact bonds, also called pay for success, let private investors fund a trial, with an outcome payer such as a government or insurer repaying them with a return only if an agreed outcome is reached. Interviewees saw promise but also high transaction costs and difficulty in measuring health outcomes.[9]
- Agency style programs such as ARPA-H can fund trials directly, as the VITAL-H contract shows.[8]
Some researchers argue the sums involved are small for large public funders. One scientist quoted by Science|Business estimated that funding major trials to establish reliable aging biomarkers would cost on the order of 70 to 100 million dollars, which he called "a drop in the ocean" for the NIH or EU budgets.[6] Faster measures of aging could also shorten future trials, a theme covered on Aging clocks and faster longevity trials.
Honest limits
The case for funding TAME is a case for getting an answer, not a promise that the answer will be yes. Metformin may not slow aging in healthy older people.
- Most of the human evidence is observational. Supporters themselves say it shows associations in people with diabetes and stops short of proving cause and effect.[1]
- A 2022 Danish registry study found that people with type 2 diabetes starting metformin had higher mortality than matched people without diabetes, including in twin pairs, which challenged an earlier finding of a survival advantage.[10]
- The MILES study, a small crossover trial of 14 people around age 70, found that six weeks of metformin changed the activity of hundreds of genes in muscle and fat tissue, including pathways linked to aging. This suggests biological effects but does not show longer or healthier lives.[11]
- A 2019 randomized trial of 53 older adults found that metformin blunted some benefits of 12 weeks of aerobic exercise, including gains in insulin sensitivity and muscle mitochondrial respiration. The authors said more studies are needed before prescribing metformin to slow aging.[12]
- While TAME waited, the field moved on. Newer trials such as VITAL-H test other drugs, some of which have commercial futures, so metformin may never be the first aging drug tested at scale.[2][8]
None of this weakens the funding argument. A large, well run trial is the way to settle these disputes, and a clear negative result would also be public knowledge worth having. Prespecified designs and open reporting, discussed on Registered reports and peer review before results, help make either outcome trustworthy.
Discussion questions, essay ideas, and learning related AI prompt ideas
- Explain why a generic drug that costs very little per dose can be harder to test than an expensive new drug, and what that reveals about how medical knowledge is produced.
- Compare grants, social impact bonds, public private partnerships, and agency programs like ARPA-H as ways to pay for a trial of an off patent drug, and judge which fits a six year aging trial best.
- Describe how a composite endpoint of several age related diseases lets researchers test aging without asking regulators to call aging a disease, and weigh the strengths and weaknesses of that design.
- Argue whether a clear negative result from a large aging trial would be worth its cost as public knowledge, and explain who would benefit from it.
- Outline a funding plan that could raise the remaining money for a public good trial within two years, naming the kinds of funders involved and the risks each would carry.
- Assess what the mixed evidence on metformin, including the exercise findings, means for how society should choose which candidate drugs get tested first.
See also
- Aging
- Classifying aging as treatable
- Aging clocks and faster trials
- WHO and old age as a diagnosis
- Old blood versus young blood
- Ovary as a test for aging drugs
- Who pays for a longer life
- Registered reports
- Abolishing aging
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Aubrey A. NPR Morning Edition report and transcript on the TAME trial, 22 April 2024.
- ↑ 2.0 2.1 2.2 Innovita Research. "TAME: The Aging Trial with Metformin That Never Enrolled a Patient." 26 September 2026.
- ↑ 3.0 3.1 3.2 3.3 3.4 Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. "Metformin as a Tool to Target Aging." Cell Metabolism, 2016.
- ↑ 4.0 4.1 American Federation for Aging Research. "AFAR Initiative in the News: NPR spotlights TAME Trial and AFAR Scientific Leadership." 2024.
- ↑ Check Hayden E. "Anti-ageing pill pushed as bona fide drug." Nature 522, 265 to 266, 17 June 2015.
- ↑ 6.0 6.1 6.2 Matthews D. "Anti-ageing therapies: have we got health research funding wrong?" Science|Business, 7 August 2025.
- ↑ Mazin A. Interview on metformin and the TAME trial. Lifespan.io, 12 August 2025.
- ↑ 8.0 8.1 8.2 UT Health San Antonio. "UT San Antonio to lead 38 million dollar national trial testing drugs to extend healthspan." 4 March 2026.
- ↑ 9.0 9.1 9.2 9.3 9.4 9.5 9.6 Verbaanderd C, Rooman I, Huys I. "Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research." Trials, 2021.
- ↑ Keys MT et al. "Reassessing the evidence of a survival advantage in Type 2 diabetes treated with metformin compared with controls without diabetes: a retrospective cohort study." International Journal of Epidemiology, 2022.
- ↑ Kulkarni AS et al. "Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults." Aging Cell, 2018.
- ↑ Konopka AR et al. "Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults." Aging Cell, 2019.